AAPL   382.97 (+0.42%)
MSFT   213.87 (+0.49%)
FB   242.64 (-0.39%)
GOOGL   1,514.67 (+0.74%)
AMZN   3,126.28 (+1.47%)
NVDA   417.95 (+2.28%)
BABA   260.48 (+1.09%)
MU   49.91 (+0.40%)
GE   6.65 (-3.20%)
AMD   56.18 (+5.15%)
T   29.64 (-2.69%)
DIS   116.27 (-0.33%)
BAC   22.49 (-2.64%)
BA   174.56 (-3.07%)
AAPL   382.97 (+0.42%)
MSFT   213.87 (+0.49%)
FB   242.64 (-0.39%)
GOOGL   1,514.67 (+0.74%)
AMZN   3,126.28 (+1.47%)
NVDA   417.95 (+2.28%)
BABA   260.48 (+1.09%)
MU   49.91 (+0.40%)
GE   6.65 (-3.20%)
AMD   56.18 (+5.15%)
T   29.64 (-2.69%)
DIS   116.27 (-0.33%)
BAC   22.49 (-2.64%)
BA   174.56 (-3.07%)
AAPL   382.97 (+0.42%)
MSFT   213.87 (+0.49%)
FB   242.64 (-0.39%)
GOOGL   1,514.67 (+0.74%)
AMZN   3,126.28 (+1.47%)
NVDA   417.95 (+2.28%)
BABA   260.48 (+1.09%)
MU   49.91 (+0.40%)
GE   6.65 (-3.20%)
AMD   56.18 (+5.15%)
T   29.64 (-2.69%)
DIS   116.27 (-0.33%)
BAC   22.49 (-2.64%)
BA   174.56 (-3.07%)
AAPL   382.97 (+0.42%)
MSFT   213.87 (+0.49%)
FB   242.64 (-0.39%)
GOOGL   1,514.67 (+0.74%)
AMZN   3,126.28 (+1.47%)
NVDA   417.95 (+2.28%)
BABA   260.48 (+1.09%)
MU   49.91 (+0.40%)
GE   6.65 (-3.20%)
AMD   56.18 (+5.15%)
T   29.64 (-2.69%)
DIS   116.27 (-0.33%)
BAC   22.49 (-2.64%)
BA   174.56 (-3.07%)
Log in

NASDAQ:NVLNNovelion Therapeutics Stock Price, Forecast & News

$0.68
0.00 (0.00 %)
(As of 07/9/2020 01:49 PM ET)
Add
Compare
Today's Range
$0.68
Now: $0.68
$0.68
50-Day Range
$0.68
MA: $0.69
$0.70
52-Week Range
$0.54
Now: $0.68
$2.35
VolumeN/A
Average Volume200,344 shs
Market Capitalization$13.34 million
P/E RatioN/A
Dividend YieldN/A
Beta2.12
Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.
Read More
Novelion Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVLN
CUSIPN/A
Phone617-500-7867

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$130.43 million
Book Value($4.69) per share

Profitability

Net Income$-108,330,000.00

Miscellaneous

Employees109
Market Cap$13.34 million
Next Earnings DateN/A
OptionableOptionable

Receive NVLN News and Ratings via Email

Sign-up to receive the latest news and ratings for NVLN and its competitors with MarketBeat's FREE daily newsletter.

Novelion Therapeutics (NASDAQ:NVLN) Frequently Asked Questions

How has Novelion Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Novelion Therapeutics' stock was trading at $0.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVLN shares have increased by 0.0% and is now trading at $0.68. View which stocks have been most impacted by Coronavirus.

How were Novelion Therapeutics' earnings last quarter?

Novelion Therapeutics Inc (NASDAQ:NVLN) issued its quarterly earnings data on Thursday, March, 14th. The biotechnology company reported ($1.03) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.90) by $0.13. The biotechnology company earned $40.71 million during the quarter, compared to analysts' expectations of $40.90 million. View Novelion Therapeutics' earnings history.

Has Novelion Therapeutics been receiving favorable news coverage?

Press coverage about NVLN stock has been trending negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novelion Therapeutics earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Novelion Therapeutics.

Who are some of Novelion Therapeutics' key competitors?

What other stocks do shareholders of Novelion Therapeutics own?

Who are Novelion Therapeutics' key executives?

Novelion Therapeutics' management team includes the following people:
  • Mr. Benjamin S. Harshbarger, Interim CEO, Gen. Counsel & Corp. Sec. (Age 50)
  • Mr. Michael D. Price, Exec. VP & CFO (Age 61)
  • Mr. Roger W. Louis, Global Chief Compliance Officer and Head of R&D (Age 63)
  • Ms. Barbara Y. Chan, VP & Chief Accounting Officer (Age 55)
  • Ms. Amanda Murphy, Director of Investor Relations & Corp. Communications

What is Novelion Therapeutics' stock symbol?

Novelion Therapeutics trades on the NASDAQ under the ticker symbol "NVLN."

How do I buy shares of Novelion Therapeutics?

Shares of NVLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novelion Therapeutics' stock price today?

One share of NVLN stock can currently be purchased for approximately $0.68.

How big of a company is Novelion Therapeutics?

Novelion Therapeutics has a market capitalization of $13.34 million and generates $130.43 million in revenue each year. Novelion Therapeutics employs 109 workers across the globe.

What is Novelion Therapeutics' official website?

The official website for Novelion Therapeutics is www.novelion.com.

How can I contact Novelion Therapeutics?

Novelion Therapeutics' mailing address is 1800 - 510 WEST GEORGIA STREET, VANCOUVER A1, V6B 0M3. The biotechnology company can be reached via phone at 617-500-7867 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.